S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

TVTX Travere Therapeutics Inc

6.7506

0.4906 (7.84%)

07 May 2024 - Closed

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Travere Therapeutics Charts.

Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Travere Therapeutics Charts.

Travere Therapeutics Inc News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 7 May 2024 (7 hours ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 7 May 2024 (8 hours ago) • Edgar (US Regulatory)

Travere Therapeutics Reports First Quarter 2024 Financial Results
Tuesday 7 May 2024 (8 hours ago) • GlobeNewswire Inc.

Travere Therapeutics to Report First Quarter 2024 Financial Results
Tuesday 30 April 2024 (1 week ago) • GlobeNewswire Inc.

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Wednesday 24 April 2024 (2 weeks ago) • GlobeNewswire Inc.

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Wednesday 24 April 2024 (2 weeks ago) • PR Newswire (US)

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Friday 5 April 2024 (1 month ago) • GlobeNewswire Inc.

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Thursday 4 April 2024 (1 month ago) • GlobeNewswire Inc.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.

Travere Therapeutics to Present at Upcoming Investor Conferences
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Saturday 24 February 2024 (2 months ago) • Edgar (US Regulatory)

More Travere Therapeutics Inc News Articles

Australian SE All Ordina...

Invesco QQQ Trust Series 1

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions